Tryptoline-based benzothiazoles re-sensitize MRSA to β-lactam antibiotics
摘要:
Resistance-modifying agents (RMAs) offer a promising solution to combat bacterial antibiotic resistance. Here we report the discovery and structure-activity relationships of a new class of RMAs with a novel tryptoline-based benzothiazole scaffold. Our most potent compound in this series (4ad) re-sensitizes multiple MRSA strains to cephalosporins at low concentrations (2 mu g/mL) and has low mammalian cytotoxicity with a half growth inhibitory concentration (GI(50)) > 100 mu g/mL in human cervical carcinoma (HeLa) cells. In addition, the same core scaffold with different substitutions also gives good antibacterial activity against MRSA.
[EN] TRYPTOLINE-BASED BENZOTHIAZOLES AND THEIR USE AS ANTIBIOTICS AND ANTIBIOTIC RESISTANCE-MODIFYING AGENTS<br/>[FR] BENZOTHIAZOLES À BASE DE TRYPTOLINE ET LEUR UTILISATION EN TANT QU'ANTIBIOTIQUES ET AGENTS MODIFIANT LA RÉSISTANCE AUX ANTIBIOTIQUES
申请人:UNIV COLORADO REGENTS
公开号:WO2021046194A1
公开(公告)日:2021-03-11
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.